nach oben

Erschienen in:

15.05.2017 | Original Article

Estimation of glomerular filtration rate in cancer patients with abnormal body composition and relation with carboplatin toxicity

verfasst von: M. Bretagne, A. Jouinot, J. P. Durand, O. Huillard, P. Boudou Rouquette, C. Tlemsani, J. Arrondeau, G. Sarfati, F. Goldwasser, J. Alexandre

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Carboplatin clearance is correlated with glomerular filtration rate (GFR) and usually estimated with creatinine clearance using Cockcroft–Gault (CG) formula. Because plasma creatinine level is highly correlated with muscle mass, we hypothesized that an abnormal body composition with a low lean body mass (LBM) percentage [(LBM/weight) × 100] may result in inadequate carboplatin dosing. Serum cystatin C is an alternative marker of GFR, not affected by muscle mass. We aimed to investigate the influence of total LBM and LBM percentage on GFR calculation, using creatinine (CrCl) or cystatin C (GFR_cysC-creat) in cancer patients.

Methods

Pretreatment serum creatinine and cystatin C were prospectively measured in consecutive patients. CrCl (CG formula), GFR_cysC-creat (CKD-EPI creatinine–cystatin equation), and LBM (CT scan) were calculated. Severe thrombocytopenia post-carboplatin were analyzed.

Results

In 131 patients without renal insufficiency, LBM was correlated with creatinine (r = 0.30, p < 0.005) but not with cystatin C (r = −0.07, p = 0.43). In patients with the lowest LBM percentage, the CrCl was significantly higher than GFR_cysC-creat indicating an overestimation of GFR with creatinine (p = 0.0004). In 24 patients treated with carboplatin AUC 5 (mg/ml min) ± paclitaxel, the risk of severe thrombocytopenia was associated with lower LBM percentage (p = 0.0002) and higher CrCl/GFR_cysC-creat ratio (p = 0.006). By ROC analysis, the CrCl/GFR_cysC-creat ratio threshold predicting severe thrombocytopenia was 1.23.

Conclusions

A low LBM percentage increases the risk of inadequate GFR calculation by CG formula, and carboplatin overdosage with severe thrombocytopenia. High CrCl/GFR_cysC-creat ratio allows the identification of these patients.

Wesson LG (1969) Renal hemodynamics in physiological states. In: Wesson LG (ed) Grune & Stratton, New York

Calvert AH, Newell DR, Gumbrell LA et al (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748–1756CrossRefPubMed

Perrone RD, Madias NE, Levey AS (1992) Serum creatinine as an index of renal function: new insights into old concepts. Clin Chem 38:1933–1953PubMed

Ekhart C, de Jonge ME, Huitema ADR et al (2006) Flat dosing of carboplatin is justified in adult patients with normal renal function. Clin Cancer Res 12:6502–6508. doi:10.1158/1078-0432.CCR-05-1076 CrossRefPubMed

Baxmann AC, Ahmed MS, Marques NC et al (2008) Influence of muscle mass and physical activity on serum and urinary creatinine and serum cystatin C. Clin J Am Soc Nephrol 3:348–354. doi:10.2215/CJN.02870707 CrossRefPubMedPubMedCentral

Dharnidharka VR, Kwon C, Stevens G (2002) Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 40:221–226. doi:10.1053/ajkd.2002.34487 CrossRefPubMed

Inker LA, Schmid CH, Tighiouart H et al (2012) Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 367:20–29. doi:10.1056/NEJMoa1114248 CrossRefPubMedPubMedCentral

Du Bois D, Du Bois EF (1989) A formula to estimate the approximate surface area if height and weight be known. 1916. Nutrition 5:303–311–313

Heymsfield SB, Wang Z, Baumgartner RN, Ross R (1997) Human body composition: advances in models and methods. Annu Rev Nutr 17:527–558. doi:10.1146/annurev.nutr.17.1.527 CrossRefPubMed

10.

Mitsiopoulos N, Baumgartner RN, Heymsfield SB et al (1998) Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography. J Appl Physiol 85:115–122PubMed

11.

Antoun S, Baracos VE, Birdsell L et al (2010) Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. Ann Oncol 21:1594–1598. doi:10.1093/annonc/mdp605 CrossRefPubMed

12.

Mourtzakis M, Prado CMM, Lieffers JR et al (2008) A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab 33:997–1006. doi:10.1139/H08-075 CrossRefPubMed

13.

Prado CMM, Lieffers JR, McCargar LJ et al (2008) Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol 9:629–635. doi:10.1016/S1470-2045(08)70153-0 CrossRefPubMed

14.

Shen W, Punyanitya M, Wang Z et al (2004) Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J Appl Physiol 97:2333–2338. doi:10.1152/japplphysiol.00744.2004 CrossRefPubMed

15.

Stevens LA, Levey AS (2007) Frequently asked questions about GFR estimates. National Kidney Foundation, New York. http://www.sfmr.se/files.aspx?f_id=61754. Accessed 11 May 2017

16.

Schmitt A, Gladieff L, Lansiaux A et al (2009) A universal formula based on cystatin C to perform individual dosing of carboplatin in normal weight, underweight, and obese patients. Clin Cancer Res 15:3633–3639. doi:10.1158/1078-0432.CCR-09-0017 CrossRefPubMed

17.

Chew JSC, Saleem M, Florkowski CM, George PM (2009) Estimating renal function in oncology patients using cystatin C-based equations. Clin Oncol (R Coll Radiol) 21:425–426. doi:10.1016/j.clon.2009.01.012 CrossRef

18.

Roos JF, Doust J, Tett SE, Kirkpatrick CMJ (2007) Diagnostic accuracy of cystatin C compared to serum creatinine for the estimation of renal dysfunction in adults and children—a meta-analysis. Clin Biochem 40:383–391. doi:10.1016/j.clinbiochem.2006.10.026 CrossRefPubMed

19.

Schmitt A, Gladieff L, Laffont CM et al (2010) Factors for hematopoietic toxicity of carboplatin: refining the targeting of carboplatin systemic exposure. J Clin Oncol 28:4568–4574. doi:10.1200/JCO.2010.29.3597 CrossRefPubMed

20.

Herrington JD, Tran HT, Riggs MW (2006) Prospective evaluation of carboplatin AUC dosing in patients with a BMI ≥ 27 or cachexia. Cancer Chemother Pharmacol 57:241–247. doi:10.1007/s00280-005-0012-9 CrossRefPubMed

21.

Ekhart C, Rodenhuis S, Schellens JHM et al (2009) Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter? Cancer Chemother Pharmacol 64:115–122. doi:10.1007/s00280-008-0856-x CrossRefPubMed

22.

Kaag D (2013) Carboplatin dose calculation in lung cancer patients with low serum creatinine concentrations using CKD-EPI and Cockcroft–Gault with different weight descriptors. Lung Cancer 79:54–58. doi:10.1016/j.lungcan.2012.10.009 CrossRefPubMed

23.

Winter MA, Guhr KN, Berg GM (2012) Impact of various body weights and serum creatinine concentrations on the bias and accuracy of the Cockcroft–Gault equation. Pharmacotherapy 32:604–612. doi:10.1002/j.1875-9114.2012.01098.x CrossRefPubMed

24.

Chu MP, McCaw L, Stretch C et al (2015) Development of a new equation to estimate creatinine clearance in cancer patients. Cancer Chemother Pharmacol 76:117–124. doi:10.1007/s00280-015-2777-9 CrossRefPubMed

Titel: Estimation of glomerular filtration rate in cancer patients with abnormal body composition and relation with carboplatin toxicity
verfasst von: M. Bretagne
A. Jouinot
J. P. Durand
O. Huillard
P. Boudou Rouquette
C. Tlemsani
J. Arrondeau
G. Sarfati
F. Goldwasser
J. Alexandre
Publikationsdatum: 15.05.2017
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 1/2017
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-017-3326-5

Neu im Fachgebiet Onkologie

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Das sind die führenden Symptome junger Darmkrebspatienten

23.05.2024 Leitsymptome in der Hausarztpraxis Nachrichten

Darmkrebserkrankungen in jüngeren Jahren sind ein zunehmendes Problem, das häufig längere Zeit übersehen wird, gerade weil die Patienten noch nicht alt sind. Welche Anzeichen Ärzte stutzig machen sollten, hat eine Metaanalyse herausgearbeitet.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Estimation of glomerular filtration rate in cancer patients with abnormal body composition and relation with carboplatin toxicity